Outlook Therapeutics, Inc. OTLK stock plunged on Thursday after the U.S. Food and Drug Administration (FDA) update.Outlook Therapeutics traded lower, with a session volume of 26.41 million compared to the average volume of 1.51 million as per data from Benzinga Pro.FDA UpdateThe agency issued a complete response letter (CRL) to its biologics license application (BLA) resubmission, indicating that the FDA cannot approve the application in its present form for the treatment of wet age-related macular degenera ...